Global Tumor Biomarker Testing Supply, Demand and Key Producers, 2026-2032
The global Tumor Biomarker Testing market size is expected to reach $ 24843 million by 2032, rising at a market growth of 10.4% CAGR during the forecast period (2026-2032).
Tumor Biomarker Testing refers to the broad category of diagnostic products and testing services used to analyze measurable features associated with malignant tumors for diagnosis, classification, therapy selection, treatment monitoring, recurrence surveillance, and prognosis assessment. The analytes covered by Tumor Biomarker Testing may include protein markers, DNA mutations, RNA fusions, copy number variations, methylation signatures, microsatellite instability, tumor mutational burden, PD-L1 expression, circulating tumor DNA, and circulating tumor cells in tissue, blood, bone marrow, cells, or other body fluid samples. In commercial form, Tumor Biomarker Testing may appear as central-laboratory testing services, PCR kits, NGS panels, IHC/ISH reagents, cartridge-based automated systems, quality controls, and integrated software-reporting solutions. Its structure usually includes sample collection and preservation media, pre-analytical reagents, amplification or hybridization chemistry, signal detection instruments, bioinformatics interpretation modules, and clinical reporting. The core principle is to convert reproducible molecular or cellular abnormalities of cancer into clinically actionable information.
The growth of Tumor Biomarker Testing is fundamentally supported by the rising global cancer burden and the deeper penetration of precision oncology. With around 20 million new cancer cases worldwide in 2022 and a continued shift toward targeted therapy, immunotherapy, and biomarker-guided treatment, clinical practice is moving from single-gene testing toward comprehensive biomarker testing and comprehensive genomic profiling. Guideline adoption and expanding drug-label linkage are driving demand for tissue testing, liquid biopsy, companion diagnostics, and MRD monitoring.
The major restraints remain access, reimbursement, standardization, and real-world implementation efficiency. Many patients still do not receive complete biomarker testing early enough in the treatment pathway, while tissue inadequacy, workflow fragmentation, inter-laboratory variability, low-shedding ctDNA, result interpretation complexity, and uneven payment coverage continue to limit adoption. For suppliers, regulatory compliance, evidence generation, quality systems, and secure data handling raise barriers to scale.
Downstream demand is shifting from one-time testing toward longitudinal, multi-sample, and multi-technology testing. Hospitals increasingly prefer integrated solutions that cover DNA, RNA, protein, and immune-related markers with faster turnaround and less tissue consumption. Advanced solid tumor care is moving toward broader pan-cancer panels and liquid biopsy, while post-surgical and treatment-monitoring settings are accelerating demand for ctDNA-MRD and recurrence surveillance. As a result, decentralized cartridge systems and centralized high-complexity genomic labs will continue to coexist, serving different clinical needs.
This report studies the global Tumor Biomarker Testing demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Tumor Biomarker Testing, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Tumor Biomarker Testing that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Tumor Biomarker Testing total market, 2021-2032, (USD Million)
Global Tumor Biomarker Testing total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Tumor Biomarker Testing total market, key domestic companies, and share, (USD Million)
Global Tumor Biomarker Testing revenue by player, revenue and market share 2021-2026, (USD Million)
Global Tumor Biomarker Testing total market by Type, CAGR, 2021-2032, (USD Million)
Global Tumor Biomarker Testing total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Tumor Biomarker Testing market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Abbott Laboratories, Agilent Technologies, Roche, Thermo Fisher Scientific, QIAGEN, Illumina, DiaSorin, Fujirebio, Siemens Healthineers, Quest Diagnostics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Tumor Biomarker Testing market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Tumor Biomarker Testing Market, By Region:
1. How big is the global Tumor Biomarker Testing market?
2. What is the demand of the global Tumor Biomarker Testing market?
3. What is the year over year growth of the global Tumor Biomarker Testing market?
4. What is the total value of the global Tumor Biomarker Testing market?
5. Who are the Major Players in the global Tumor Biomarker Testing market?
6. What are the growth factors driving the market demand?
Tumor Biomarker Testing refers to the broad category of diagnostic products and testing services used to analyze measurable features associated with malignant tumors for diagnosis, classification, therapy selection, treatment monitoring, recurrence surveillance, and prognosis assessment. The analytes covered by Tumor Biomarker Testing may include protein markers, DNA mutations, RNA fusions, copy number variations, methylation signatures, microsatellite instability, tumor mutational burden, PD-L1 expression, circulating tumor DNA, and circulating tumor cells in tissue, blood, bone marrow, cells, or other body fluid samples. In commercial form, Tumor Biomarker Testing may appear as central-laboratory testing services, PCR kits, NGS panels, IHC/ISH reagents, cartridge-based automated systems, quality controls, and integrated software-reporting solutions. Its structure usually includes sample collection and preservation media, pre-analytical reagents, amplification or hybridization chemistry, signal detection instruments, bioinformatics interpretation modules, and clinical reporting. The core principle is to convert reproducible molecular or cellular abnormalities of cancer into clinically actionable information.
The growth of Tumor Biomarker Testing is fundamentally supported by the rising global cancer burden and the deeper penetration of precision oncology. With around 20 million new cancer cases worldwide in 2022 and a continued shift toward targeted therapy, immunotherapy, and biomarker-guided treatment, clinical practice is moving from single-gene testing toward comprehensive biomarker testing and comprehensive genomic profiling. Guideline adoption and expanding drug-label linkage are driving demand for tissue testing, liquid biopsy, companion diagnostics, and MRD monitoring.
The major restraints remain access, reimbursement, standardization, and real-world implementation efficiency. Many patients still do not receive complete biomarker testing early enough in the treatment pathway, while tissue inadequacy, workflow fragmentation, inter-laboratory variability, low-shedding ctDNA, result interpretation complexity, and uneven payment coverage continue to limit adoption. For suppliers, regulatory compliance, evidence generation, quality systems, and secure data handling raise barriers to scale.
Downstream demand is shifting from one-time testing toward longitudinal, multi-sample, and multi-technology testing. Hospitals increasingly prefer integrated solutions that cover DNA, RNA, protein, and immune-related markers with faster turnaround and less tissue consumption. Advanced solid tumor care is moving toward broader pan-cancer panels and liquid biopsy, while post-surgical and treatment-monitoring settings are accelerating demand for ctDNA-MRD and recurrence surveillance. As a result, decentralized cartridge systems and centralized high-complexity genomic labs will continue to coexist, serving different clinical needs.
This report studies the global Tumor Biomarker Testing demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Tumor Biomarker Testing, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Tumor Biomarker Testing that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Tumor Biomarker Testing total market, 2021-2032, (USD Million)
Global Tumor Biomarker Testing total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Tumor Biomarker Testing total market, key domestic companies, and share, (USD Million)
Global Tumor Biomarker Testing revenue by player, revenue and market share 2021-2026, (USD Million)
Global Tumor Biomarker Testing total market by Type, CAGR, 2021-2032, (USD Million)
Global Tumor Biomarker Testing total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Tumor Biomarker Testing market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Abbott Laboratories, Agilent Technologies, Roche, Thermo Fisher Scientific, QIAGEN, Illumina, DiaSorin, Fujirebio, Siemens Healthineers, Quest Diagnostics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Tumor Biomarker Testing market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Tumor Biomarker Testing Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- DNA Biomarker Testing
- RNA Biomarker Testing
- Protein Biomarker Testing
- Cell-based Biomarker Testing
- Multi-analyte Biomarker Testing
- Tissue-based Testing
- Blood-based Testing
- Bone Marrow-based Testing
- Other Body Fluid-based Testing
- Central Laboratory Testing
- Hospital In-house Testing
- Sequencing-based Testing
- PCR-based Testing
- Immunoassay-based Testing
- Hybridization-based Testing
- Cell Analysis-based Testing
- Lung Cancer
- Breast Cancer
- Colorectal
- Prostate Cancer
- Blood Cancer
- Abbott Laboratories
- Agilent Technologies
- Roche
- Thermo Fisher Scientific
- QIAGEN
- Illumina
- DiaSorin
- Fujirebio
- Siemens Healthineers
- Quest Diagnostics
- Labcorp
- NeoGenomics
- Exact Sciences
- Myriad Genetics
- Guardant Health
- Caris Life Sciences
- Tempus AI
- Natera
- Personalis
- Invivoscribe
- Biocartis
- Sysmex
- Leica Biosystems
- Cepheid
- Menarini Silicon Biosystems
- Veracyte
- Castle Biosciences
- OncoDNA
- ACT Genomics
- GC Genome
- Burning Rock
- Amoy Diagnostics
- Genetron Health
- 3DMed Diagnostics
- Singlera Genomics
- BGI Genomics
- Geneseeq
- Genecast
1. How big is the global Tumor Biomarker Testing market?
2. What is the demand of the global Tumor Biomarker Testing market?
3. What is the year over year growth of the global Tumor Biomarker Testing market?
4. What is the total value of the global Tumor Biomarker Testing market?
5. Who are the Major Players in the global Tumor Biomarker Testing market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Tumor Biomarker Testing Introduction
1.2 World Tumor Biomarker Testing Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Tumor Biomarker Testing Total Market by Region (by Headquarter Location)
1.3.1 World Tumor Biomarker Testing Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Tumor Biomarker Testing Revenue (2021-2032)
1.3.3 China Based Company Tumor Biomarker Testing Revenue (2021-2032)
1.3.4 Europe Based Company Tumor Biomarker Testing Revenue (2021-2032)
1.3.5 Japan Based Company Tumor Biomarker Testing Revenue (2021-2032)
1.3.6 South Korea Based Company Tumor Biomarker Testing Revenue (2021-2032)
1.3.7 ASEAN Based Company Tumor Biomarker Testing Revenue (2021-2032)
1.3.8 India Based Company Tumor Biomarker Testing Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Tumor Biomarker Testing Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Tumor Biomarker Testing Consumption Value (2021-2032)
2.2 World Tumor Biomarker Testing Consumption Value by Region
2.2.1 World Tumor Biomarker Testing Consumption Value by Region (2021-2026)
2.2.2 World Tumor Biomarker Testing Consumption Value Forecast by Region (2027-2032)
2.3 United States Tumor Biomarker Testing Consumption Value (2021-2032)
2.4 China Tumor Biomarker Testing Consumption Value (2021-2032)
2.5 Europe Tumor Biomarker Testing Consumption Value (2021-2032)
2.6 Japan Tumor Biomarker Testing Consumption Value (2021-2032)
2.7 South Korea Tumor Biomarker Testing Consumption Value (2021-2032)
2.8 ASEAN Tumor Biomarker Testing Consumption Value (2021-2032)
2.9 India Tumor Biomarker Testing Consumption Value (2021-2032)
3 WORLD TUMOR BIOMARKER TESTING COMPANIES COMPETITIVE ANALYSIS
3.1 World Tumor Biomarker Testing Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Tumor Biomarker Testing Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Tumor Biomarker Testing in 2025
3.2.3 Global Concentration Ratios (CR8) for Tumor Biomarker Testing in 2025
3.3 Tumor Biomarker Testing Company Evaluation Quadrant
3.4 Tumor Biomarker Testing Market: Overall Company Footprint Analysis
3.4.1 Tumor Biomarker Testing Market: Region Footprint
3.4.2 Tumor Biomarker Testing Market: Company Product Type Footprint
3.4.3 Tumor Biomarker Testing Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Tumor Biomarker Testing Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Tumor Biomarker Testing Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Tumor Biomarker Testing Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Tumor Biomarker Testing Consumption Value Comparison
4.2.1 United States VS China: Tumor Biomarker Testing Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Tumor Biomarker Testing Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Tumor Biomarker Testing Companies and Market Share, 2021-2026
4.3.1 United States Based Tumor Biomarker Testing Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Tumor Biomarker Testing Revenue, (2021-2026)
4.4 China Based Companies Tumor Biomarker Testing Revenue and Market Share, 2021-2026
4.4.1 China Based Tumor Biomarker Testing Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Tumor Biomarker Testing Revenue, (2021-2026)
4.5 Rest of World Based Tumor Biomarker Testing Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Tumor Biomarker Testing Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Tumor Biomarker Testing Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Tumor Biomarker Testing Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 DNA Biomarker Testing
5.2.2 RNA Biomarker Testing
5.2.3 Protein Biomarker Testing
5.2.4 Cell-based Biomarker Testing
5.2.5 Multi-analyte Biomarker Testing
5.3 Market Segment by Type
5.3.1 World Tumor Biomarker Testing Market Size by Type (2021-2026)
5.3.2 World Tumor Biomarker Testing Market Size by Type (2027-2032)
5.3.3 World Tumor Biomarker Testing Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY SAMPLE SOURCE
6.1 World Tumor Biomarker Testing Market Size Overview by Sample Source: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Sample Source
6.2.1 Tissue-based Testing
6.2.2 Blood-based Testing
6.2.3 Bone Marrow-based Testing
6.2.4 Other Body Fluid-based Testing
6.3 Market Segment by Sample Source
6.3.1 World Tumor Biomarker Testing Market Size by Sample Source (2021-2026)
6.3.2 World Tumor Biomarker Testing Market Size by Sample Source (2027-2032)
6.3.3 World Tumor Biomarker Testing Market Size Market Share by Sample Source (2027-2032)
7 MARKET ANALYSIS BY DELIVERY MODEL
7.1 World Tumor Biomarker Testing Market Size Overview by Delivery Model: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Delivery Model
7.2.1 Central Laboratory Testing
7.2.2 Hospital In-house Testing
7.3 Market Segment by Delivery Model
7.3.1 World Tumor Biomarker Testing Market Size by Delivery Model (2021-2026)
7.3.2 World Tumor Biomarker Testing Market Size by Delivery Model (2027-2032)
7.3.3 World Tumor Biomarker Testing Market Size Market Share by Delivery Model (2027-2032)
8 MARKET ANALYSIS BY DETECTION TECHNOLOGY
8.1 World Tumor Biomarker Testing Market Size Overview by Detection Technology: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Detection Technology
8.2.1 Sequencing-based Testing
8.2.2 PCR-based Testing
8.2.3 Immunoassay-based Testing
8.2.4 Hybridization-based Testing
8.2.5 Cell Analysis-based Testing
8.3 Market Segment by Detection Technology
8.3.1 World Tumor Biomarker Testing Market Size by Detection Technology (2021-2026)
8.3.2 World Tumor Biomarker Testing Market Size by Detection Technology (2027-2032)
8.3.3 World Tumor Biomarker Testing Market Size Market Share by Detection Technology (2027-2032)
9 MARKET ANALYSIS BY APPLICATION
9.1 World Tumor Biomarker Testing Market Size Overview by Application: 2021 VS 2025 VS 2032
9.2 Segment Introduction by Application
9.2.1 Lung Cancer
9.2.2 Breast Cancer
9.2.3 Colorectal
9.2.4 Prostate Cancer
9.2.5 Blood Cancer
9.3 Market Segment by Application
9.3.1 World Tumor Biomarker Testing Market Size by Application (2021-2026)
9.3.2 World Tumor Biomarker Testing Market Size by Application (2027-2032)
9.3.3 World Tumor Biomarker Testing Market Size Market Share by Application (2021-2032)
10 COMPANY PROFILES
10.1 Abbott Laboratories
10.1.1 Abbott Laboratories Details
10.1.2 Abbott Laboratories Major Business
10.1.3 Abbott Laboratories Tumor Biomarker Testing Product and Services
10.1.4 Abbott Laboratories Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.1.5 Abbott Laboratories Recent Developments/Updates
10.1.6 Abbott Laboratories Competitive Strengths & Weaknesses
10.2 Agilent Technologies
10.2.1 Agilent Technologies Details
10.2.2 Agilent Technologies Major Business
10.2.3 Agilent Technologies Tumor Biomarker Testing Product and Services
10.2.4 Agilent Technologies Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.2.5 Agilent Technologies Recent Developments/Updates
10.2.6 Agilent Technologies Competitive Strengths & Weaknesses
10.3 Roche
10.3.1 Roche Details
10.3.2 Roche Major Business
10.3.3 Roche Tumor Biomarker Testing Product and Services
10.3.4 Roche Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.3.5 Roche Recent Developments/Updates
10.3.6 Roche Competitive Strengths & Weaknesses
10.4 Thermo Fisher Scientific
10.4.1 Thermo Fisher Scientific Details
10.4.2 Thermo Fisher Scientific Major Business
10.4.3 Thermo Fisher Scientific Tumor Biomarker Testing Product and Services
10.4.4 Thermo Fisher Scientific Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.4.5 Thermo Fisher Scientific Recent Developments/Updates
10.4.6 Thermo Fisher Scientific Competitive Strengths & Weaknesses
10.5 QIAGEN
10.5.1 QIAGEN Details
10.5.2 QIAGEN Major Business
10.5.3 QIAGEN Tumor Biomarker Testing Product and Services
10.5.4 QIAGEN Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.5.5 QIAGEN Recent Developments/Updates
10.5.6 QIAGEN Competitive Strengths & Weaknesses
10.6 Illumina
10.6.1 Illumina Details
10.6.2 Illumina Major Business
10.6.3 Illumina Tumor Biomarker Testing Product and Services
10.6.4 Illumina Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.6.5 Illumina Recent Developments/Updates
10.6.6 Illumina Competitive Strengths & Weaknesses
10.7 DiaSorin
10.7.1 DiaSorin Details
10.7.2 DiaSorin Major Business
10.7.3 DiaSorin Tumor Biomarker Testing Product and Services
10.7.4 DiaSorin Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.7.5 DiaSorin Recent Developments/Updates
10.7.6 DiaSorin Competitive Strengths & Weaknesses
10.8 Fujirebio
10.8.1 Fujirebio Details
10.8.2 Fujirebio Major Business
10.8.3 Fujirebio Tumor Biomarker Testing Product and Services
10.8.4 Fujirebio Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.8.5 Fujirebio Recent Developments/Updates
10.8.6 Fujirebio Competitive Strengths & Weaknesses
10.9 Siemens Healthineers
10.9.1 Siemens Healthineers Details
10.9.2 Siemens Healthineers Major Business
10.9.3 Siemens Healthineers Tumor Biomarker Testing Product and Services
10.9.4 Siemens Healthineers Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.9.5 Siemens Healthineers Recent Developments/Updates
10.9.6 Siemens Healthineers Competitive Strengths & Weaknesses
10.10 Quest Diagnostics
10.10.1 Quest Diagnostics Details
10.10.2 Quest Diagnostics Major Business
10.10.3 Quest Diagnostics Tumor Biomarker Testing Product and Services
10.10.4 Quest Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.10.5 Quest Diagnostics Recent Developments/Updates
10.10.6 Quest Diagnostics Competitive Strengths & Weaknesses
10.11 Labcorp
10.11.1 Labcorp Details
10.11.2 Labcorp Major Business
10.11.3 Labcorp Tumor Biomarker Testing Product and Services
10.11.4 Labcorp Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.11.5 Labcorp Recent Developments/Updates
10.11.6 Labcorp Competitive Strengths & Weaknesses
10.12 NeoGenomics
10.12.1 NeoGenomics Details
10.12.2 NeoGenomics Major Business
10.12.3 NeoGenomics Tumor Biomarker Testing Product and Services
10.12.4 NeoGenomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.12.5 NeoGenomics Recent Developments/Updates
10.12.6 NeoGenomics Competitive Strengths & Weaknesses
10.13 Exact Sciences
10.13.1 Exact Sciences Details
10.13.2 Exact Sciences Major Business
10.13.3 Exact Sciences Tumor Biomarker Testing Product and Services
10.13.4 Exact Sciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.13.5 Exact Sciences Recent Developments/Updates
10.13.6 Exact Sciences Competitive Strengths & Weaknesses
10.14 Myriad Genetics
10.14.1 Myriad Genetics Details
10.14.2 Myriad Genetics Major Business
10.14.3 Myriad Genetics Tumor Biomarker Testing Product and Services
10.14.4 Myriad Genetics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.14.5 Myriad Genetics Recent Developments/Updates
10.14.6 Myriad Genetics Competitive Strengths & Weaknesses
10.15 Guardant Health
10.15.1 Guardant Health Details
10.15.2 Guardant Health Major Business
10.15.3 Guardant Health Tumor Biomarker Testing Product and Services
10.15.4 Guardant Health Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.15.5 Guardant Health Recent Developments/Updates
10.15.6 Guardant Health Competitive Strengths & Weaknesses
10.16 Caris Life Sciences
10.16.1 Caris Life Sciences Details
10.16.2 Caris Life Sciences Major Business
10.16.3 Caris Life Sciences Tumor Biomarker Testing Product and Services
10.16.4 Caris Life Sciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.16.5 Caris Life Sciences Recent Developments/Updates
10.16.6 Caris Life Sciences Competitive Strengths & Weaknesses
10.17 Tempus AI
10.17.1 Tempus AI Details
10.17.2 Tempus AI Major Business
10.17.3 Tempus AI Tumor Biomarker Testing Product and Services
10.17.4 Tempus AI Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.17.5 Tempus AI Recent Developments/Updates
10.17.6 Tempus AI Competitive Strengths & Weaknesses
10.18 Natera
10.18.1 Natera Details
10.18.2 Natera Major Business
10.18.3 Natera Tumor Biomarker Testing Product and Services
10.18.4 Natera Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.18.5 Natera Recent Developments/Updates
10.18.6 Natera Competitive Strengths & Weaknesses
10.19 Personalis
10.19.1 Personalis Details
10.19.2 Personalis Major Business
10.19.3 Personalis Tumor Biomarker Testing Product and Services
10.19.4 Personalis Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.19.5 Personalis Recent Developments/Updates
10.19.6 Personalis Competitive Strengths & Weaknesses
10.20 Invivoscribe
10.20.1 Invivoscribe Details
10.20.2 Invivoscribe Major Business
10.20.3 Invivoscribe Tumor Biomarker Testing Product and Services
10.20.4 Invivoscribe Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.20.5 Invivoscribe Recent Developments/Updates
10.20.6 Invivoscribe Competitive Strengths & Weaknesses
10.21 Biocartis
10.21.1 Biocartis Details
10.21.2 Biocartis Major Business
10.21.3 Biocartis Tumor Biomarker Testing Product and Services
10.21.4 Biocartis Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.21.5 Biocartis Recent Developments/Updates
10.21.6 Biocartis Competitive Strengths & Weaknesses
10.22 Sysmex
10.22.1 Sysmex Details
10.22.2 Sysmex Major Business
10.22.3 Sysmex Tumor Biomarker Testing Product and Services
10.22.4 Sysmex Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.22.5 Sysmex Recent Developments/Updates
10.22.6 Sysmex Competitive Strengths & Weaknesses
10.23 Leica Biosystems
10.23.1 Leica Biosystems Details
10.23.2 Leica Biosystems Major Business
10.23.3 Leica Biosystems Tumor Biomarker Testing Product and Services
10.23.4 Leica Biosystems Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.23.5 Leica Biosystems Recent Developments/Updates
10.23.6 Leica Biosystems Competitive Strengths & Weaknesses
10.24 Cepheid
10.24.1 Cepheid Details
10.24.2 Cepheid Major Business
10.24.3 Cepheid Tumor Biomarker Testing Product and Services
10.24.4 Cepheid Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.24.5 Cepheid Recent Developments/Updates
10.24.6 Cepheid Competitive Strengths & Weaknesses
10.25 Menarini Silicon Biosystems
10.25.1 Menarini Silicon Biosystems Details
10.25.2 Menarini Silicon Biosystems Major Business
10.25.3 Menarini Silicon Biosystems Tumor Biomarker Testing Product and Services
10.25.4 Menarini Silicon Biosystems Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.25.5 Menarini Silicon Biosystems Recent Developments/Updates
10.25.6 Menarini Silicon Biosystems Competitive Strengths & Weaknesses
10.26 Veracyte
10.26.1 Veracyte Details
10.26.2 Veracyte Major Business
10.26.3 Veracyte Tumor Biomarker Testing Product and Services
10.26.4 Veracyte Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.26.5 Veracyte Recent Developments/Updates
10.26.6 Veracyte Competitive Strengths & Weaknesses
10.27 Castle Biosciences
10.27.1 Castle Biosciences Details
10.27.2 Castle Biosciences Major Business
10.27.3 Castle Biosciences Tumor Biomarker Testing Product and Services
10.27.4 Castle Biosciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.27.5 Castle Biosciences Recent Developments/Updates
10.27.6 Castle Biosciences Competitive Strengths & Weaknesses
10.28 OncoDNA
10.28.1 OncoDNA Details
10.28.2 OncoDNA Major Business
10.28.3 OncoDNA Tumor Biomarker Testing Product and Services
10.28.4 OncoDNA Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.28.5 OncoDNA Recent Developments/Updates
10.28.6 OncoDNA Competitive Strengths & Weaknesses
10.29 ACT Genomics
10.29.1 ACT Genomics Details
10.29.2 ACT Genomics Major Business
10.29.3 ACT Genomics Tumor Biomarker Testing Product and Services
10.29.4 ACT Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.29.5 ACT Genomics Recent Developments/Updates
10.29.6 ACT Genomics Competitive Strengths & Weaknesses
10.30 GC Genome
10.30.1 GC Genome Details
10.30.2 GC Genome Major Business
10.30.3 GC Genome Tumor Biomarker Testing Product and Services
10.30.4 GC Genome Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.30.5 GC Genome Recent Developments/Updates
10.30.6 GC Genome Competitive Strengths & Weaknesses
10.31 Burning Rock
10.31.1 Burning Rock Details
10.31.2 Burning Rock Major Business
10.31.3 Burning Rock Tumor Biomarker Testing Product and Services
10.31.4 Burning Rock Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.31.5 Burning Rock Recent Developments/Updates
10.31.6 Burning Rock Competitive Strengths & Weaknesses
10.32 Amoy Diagnostics
10.32.1 Amoy Diagnostics Details
10.32.2 Amoy Diagnostics Major Business
10.32.3 Amoy Diagnostics Tumor Biomarker Testing Product and Services
10.32.4 Amoy Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.32.5 Amoy Diagnostics Recent Developments/Updates
10.32.6 Amoy Diagnostics Competitive Strengths & Weaknesses
10.33 Genetron Health
10.33.1 Genetron Health Details
10.33.2 Genetron Health Major Business
10.33.3 Genetron Health Tumor Biomarker Testing Product and Services
10.33.4 Genetron Health Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.33.5 Genetron Health Recent Developments/Updates
10.33.6 Genetron Health Competitive Strengths & Weaknesses
10.34 3DMed Diagnostics
10.34.1 3DMed Diagnostics Details
10.34.2 3DMed Diagnostics Major Business
10.34.3 3DMed Diagnostics Tumor Biomarker Testing Product and Services
10.34.4 3DMed Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.34.5 3DMed Diagnostics Recent Developments/Updates
10.34.6 3DMed Diagnostics Competitive Strengths & Weaknesses
10.35 Singlera Genomics
10.35.1 Singlera Genomics Details
10.35.2 Singlera Genomics Major Business
10.35.3 Singlera Genomics Tumor Biomarker Testing Product and Services
10.35.4 Singlera Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.35.5 Singlera Genomics Recent Developments/Updates
10.35.6 Singlera Genomics Competitive Strengths & Weaknesses
10.36 BGI Genomics
10.36.1 BGI Genomics Details
10.36.2 BGI Genomics Major Business
10.36.3 BGI Genomics Tumor Biomarker Testing Product and Services
10.36.4 BGI Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.36.5 BGI Genomics Recent Developments/Updates
10.36.6 BGI Genomics Competitive Strengths & Weaknesses
10.37 Geneseeq
10.37.1 Geneseeq Details
10.37.2 Geneseeq Major Business
10.37.3 Geneseeq Tumor Biomarker Testing Product and Services
10.37.4 Geneseeq Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.37.5 Geneseeq Recent Developments/Updates
10.37.6 Geneseeq Competitive Strengths & Weaknesses
10.38 Genecast
10.38.1 Genecast Details
10.38.2 Genecast Major Business
10.38.3 Genecast Tumor Biomarker Testing Product and Services
10.38.4 Genecast Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.38.5 Genecast Recent Developments/Updates
10.38.6 Genecast Competitive Strengths & Weaknesses
11 INDUSTRY CHAIN ANALYSIS
11.1 Tumor Biomarker Testing Industry Chain
11.2 Tumor Biomarker Testing Upstream Analysis
11.3 Tumor Biomarker Testing Midstream Analysis
11.4 Tumor Biomarker Testing Downstream Analysis
12 RESEARCH FINDINGS AND CONCLUSION
13 APPENDIX
13.1 Methodology
13.2 Research Process and Data Source
13.3 Disclaimer
1.1 Tumor Biomarker Testing Introduction
1.2 World Tumor Biomarker Testing Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Tumor Biomarker Testing Total Market by Region (by Headquarter Location)
1.3.1 World Tumor Biomarker Testing Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Tumor Biomarker Testing Revenue (2021-2032)
1.3.3 China Based Company Tumor Biomarker Testing Revenue (2021-2032)
1.3.4 Europe Based Company Tumor Biomarker Testing Revenue (2021-2032)
1.3.5 Japan Based Company Tumor Biomarker Testing Revenue (2021-2032)
1.3.6 South Korea Based Company Tumor Biomarker Testing Revenue (2021-2032)
1.3.7 ASEAN Based Company Tumor Biomarker Testing Revenue (2021-2032)
1.3.8 India Based Company Tumor Biomarker Testing Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Tumor Biomarker Testing Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Tumor Biomarker Testing Consumption Value (2021-2032)
2.2 World Tumor Biomarker Testing Consumption Value by Region
2.2.1 World Tumor Biomarker Testing Consumption Value by Region (2021-2026)
2.2.2 World Tumor Biomarker Testing Consumption Value Forecast by Region (2027-2032)
2.3 United States Tumor Biomarker Testing Consumption Value (2021-2032)
2.4 China Tumor Biomarker Testing Consumption Value (2021-2032)
2.5 Europe Tumor Biomarker Testing Consumption Value (2021-2032)
2.6 Japan Tumor Biomarker Testing Consumption Value (2021-2032)
2.7 South Korea Tumor Biomarker Testing Consumption Value (2021-2032)
2.8 ASEAN Tumor Biomarker Testing Consumption Value (2021-2032)
2.9 India Tumor Biomarker Testing Consumption Value (2021-2032)
3 WORLD TUMOR BIOMARKER TESTING COMPANIES COMPETITIVE ANALYSIS
3.1 World Tumor Biomarker Testing Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Tumor Biomarker Testing Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Tumor Biomarker Testing in 2025
3.2.3 Global Concentration Ratios (CR8) for Tumor Biomarker Testing in 2025
3.3 Tumor Biomarker Testing Company Evaluation Quadrant
3.4 Tumor Biomarker Testing Market: Overall Company Footprint Analysis
3.4.1 Tumor Biomarker Testing Market: Region Footprint
3.4.2 Tumor Biomarker Testing Market: Company Product Type Footprint
3.4.3 Tumor Biomarker Testing Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Tumor Biomarker Testing Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Tumor Biomarker Testing Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Tumor Biomarker Testing Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Tumor Biomarker Testing Consumption Value Comparison
4.2.1 United States VS China: Tumor Biomarker Testing Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Tumor Biomarker Testing Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Tumor Biomarker Testing Companies and Market Share, 2021-2026
4.3.1 United States Based Tumor Biomarker Testing Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Tumor Biomarker Testing Revenue, (2021-2026)
4.4 China Based Companies Tumor Biomarker Testing Revenue and Market Share, 2021-2026
4.4.1 China Based Tumor Biomarker Testing Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Tumor Biomarker Testing Revenue, (2021-2026)
4.5 Rest of World Based Tumor Biomarker Testing Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Tumor Biomarker Testing Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Tumor Biomarker Testing Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Tumor Biomarker Testing Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 DNA Biomarker Testing
5.2.2 RNA Biomarker Testing
5.2.3 Protein Biomarker Testing
5.2.4 Cell-based Biomarker Testing
5.2.5 Multi-analyte Biomarker Testing
5.3 Market Segment by Type
5.3.1 World Tumor Biomarker Testing Market Size by Type (2021-2026)
5.3.2 World Tumor Biomarker Testing Market Size by Type (2027-2032)
5.3.3 World Tumor Biomarker Testing Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY SAMPLE SOURCE
6.1 World Tumor Biomarker Testing Market Size Overview by Sample Source: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Sample Source
6.2.1 Tissue-based Testing
6.2.2 Blood-based Testing
6.2.3 Bone Marrow-based Testing
6.2.4 Other Body Fluid-based Testing
6.3 Market Segment by Sample Source
6.3.1 World Tumor Biomarker Testing Market Size by Sample Source (2021-2026)
6.3.2 World Tumor Biomarker Testing Market Size by Sample Source (2027-2032)
6.3.3 World Tumor Biomarker Testing Market Size Market Share by Sample Source (2027-2032)
7 MARKET ANALYSIS BY DELIVERY MODEL
7.1 World Tumor Biomarker Testing Market Size Overview by Delivery Model: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Delivery Model
7.2.1 Central Laboratory Testing
7.2.2 Hospital In-house Testing
7.3 Market Segment by Delivery Model
7.3.1 World Tumor Biomarker Testing Market Size by Delivery Model (2021-2026)
7.3.2 World Tumor Biomarker Testing Market Size by Delivery Model (2027-2032)
7.3.3 World Tumor Biomarker Testing Market Size Market Share by Delivery Model (2027-2032)
8 MARKET ANALYSIS BY DETECTION TECHNOLOGY
8.1 World Tumor Biomarker Testing Market Size Overview by Detection Technology: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Detection Technology
8.2.1 Sequencing-based Testing
8.2.2 PCR-based Testing
8.2.3 Immunoassay-based Testing
8.2.4 Hybridization-based Testing
8.2.5 Cell Analysis-based Testing
8.3 Market Segment by Detection Technology
8.3.1 World Tumor Biomarker Testing Market Size by Detection Technology (2021-2026)
8.3.2 World Tumor Biomarker Testing Market Size by Detection Technology (2027-2032)
8.3.3 World Tumor Biomarker Testing Market Size Market Share by Detection Technology (2027-2032)
9 MARKET ANALYSIS BY APPLICATION
9.1 World Tumor Biomarker Testing Market Size Overview by Application: 2021 VS 2025 VS 2032
9.2 Segment Introduction by Application
9.2.1 Lung Cancer
9.2.2 Breast Cancer
9.2.3 Colorectal
9.2.4 Prostate Cancer
9.2.5 Blood Cancer
9.3 Market Segment by Application
9.3.1 World Tumor Biomarker Testing Market Size by Application (2021-2026)
9.3.2 World Tumor Biomarker Testing Market Size by Application (2027-2032)
9.3.3 World Tumor Biomarker Testing Market Size Market Share by Application (2021-2032)
10 COMPANY PROFILES
10.1 Abbott Laboratories
10.1.1 Abbott Laboratories Details
10.1.2 Abbott Laboratories Major Business
10.1.3 Abbott Laboratories Tumor Biomarker Testing Product and Services
10.1.4 Abbott Laboratories Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.1.5 Abbott Laboratories Recent Developments/Updates
10.1.6 Abbott Laboratories Competitive Strengths & Weaknesses
10.2 Agilent Technologies
10.2.1 Agilent Technologies Details
10.2.2 Agilent Technologies Major Business
10.2.3 Agilent Technologies Tumor Biomarker Testing Product and Services
10.2.4 Agilent Technologies Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.2.5 Agilent Technologies Recent Developments/Updates
10.2.6 Agilent Technologies Competitive Strengths & Weaknesses
10.3 Roche
10.3.1 Roche Details
10.3.2 Roche Major Business
10.3.3 Roche Tumor Biomarker Testing Product and Services
10.3.4 Roche Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.3.5 Roche Recent Developments/Updates
10.3.6 Roche Competitive Strengths & Weaknesses
10.4 Thermo Fisher Scientific
10.4.1 Thermo Fisher Scientific Details
10.4.2 Thermo Fisher Scientific Major Business
10.4.3 Thermo Fisher Scientific Tumor Biomarker Testing Product and Services
10.4.4 Thermo Fisher Scientific Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.4.5 Thermo Fisher Scientific Recent Developments/Updates
10.4.6 Thermo Fisher Scientific Competitive Strengths & Weaknesses
10.5 QIAGEN
10.5.1 QIAGEN Details
10.5.2 QIAGEN Major Business
10.5.3 QIAGEN Tumor Biomarker Testing Product and Services
10.5.4 QIAGEN Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.5.5 QIAGEN Recent Developments/Updates
10.5.6 QIAGEN Competitive Strengths & Weaknesses
10.6 Illumina
10.6.1 Illumina Details
10.6.2 Illumina Major Business
10.6.3 Illumina Tumor Biomarker Testing Product and Services
10.6.4 Illumina Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.6.5 Illumina Recent Developments/Updates
10.6.6 Illumina Competitive Strengths & Weaknesses
10.7 DiaSorin
10.7.1 DiaSorin Details
10.7.2 DiaSorin Major Business
10.7.3 DiaSorin Tumor Biomarker Testing Product and Services
10.7.4 DiaSorin Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.7.5 DiaSorin Recent Developments/Updates
10.7.6 DiaSorin Competitive Strengths & Weaknesses
10.8 Fujirebio
10.8.1 Fujirebio Details
10.8.2 Fujirebio Major Business
10.8.3 Fujirebio Tumor Biomarker Testing Product and Services
10.8.4 Fujirebio Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.8.5 Fujirebio Recent Developments/Updates
10.8.6 Fujirebio Competitive Strengths & Weaknesses
10.9 Siemens Healthineers
10.9.1 Siemens Healthineers Details
10.9.2 Siemens Healthineers Major Business
10.9.3 Siemens Healthineers Tumor Biomarker Testing Product and Services
10.9.4 Siemens Healthineers Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.9.5 Siemens Healthineers Recent Developments/Updates
10.9.6 Siemens Healthineers Competitive Strengths & Weaknesses
10.10 Quest Diagnostics
10.10.1 Quest Diagnostics Details
10.10.2 Quest Diagnostics Major Business
10.10.3 Quest Diagnostics Tumor Biomarker Testing Product and Services
10.10.4 Quest Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.10.5 Quest Diagnostics Recent Developments/Updates
10.10.6 Quest Diagnostics Competitive Strengths & Weaknesses
10.11 Labcorp
10.11.1 Labcorp Details
10.11.2 Labcorp Major Business
10.11.3 Labcorp Tumor Biomarker Testing Product and Services
10.11.4 Labcorp Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.11.5 Labcorp Recent Developments/Updates
10.11.6 Labcorp Competitive Strengths & Weaknesses
10.12 NeoGenomics
10.12.1 NeoGenomics Details
10.12.2 NeoGenomics Major Business
10.12.3 NeoGenomics Tumor Biomarker Testing Product and Services
10.12.4 NeoGenomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.12.5 NeoGenomics Recent Developments/Updates
10.12.6 NeoGenomics Competitive Strengths & Weaknesses
10.13 Exact Sciences
10.13.1 Exact Sciences Details
10.13.2 Exact Sciences Major Business
10.13.3 Exact Sciences Tumor Biomarker Testing Product and Services
10.13.4 Exact Sciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.13.5 Exact Sciences Recent Developments/Updates
10.13.6 Exact Sciences Competitive Strengths & Weaknesses
10.14 Myriad Genetics
10.14.1 Myriad Genetics Details
10.14.2 Myriad Genetics Major Business
10.14.3 Myriad Genetics Tumor Biomarker Testing Product and Services
10.14.4 Myriad Genetics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.14.5 Myriad Genetics Recent Developments/Updates
10.14.6 Myriad Genetics Competitive Strengths & Weaknesses
10.15 Guardant Health
10.15.1 Guardant Health Details
10.15.2 Guardant Health Major Business
10.15.3 Guardant Health Tumor Biomarker Testing Product and Services
10.15.4 Guardant Health Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.15.5 Guardant Health Recent Developments/Updates
10.15.6 Guardant Health Competitive Strengths & Weaknesses
10.16 Caris Life Sciences
10.16.1 Caris Life Sciences Details
10.16.2 Caris Life Sciences Major Business
10.16.3 Caris Life Sciences Tumor Biomarker Testing Product and Services
10.16.4 Caris Life Sciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.16.5 Caris Life Sciences Recent Developments/Updates
10.16.6 Caris Life Sciences Competitive Strengths & Weaknesses
10.17 Tempus AI
10.17.1 Tempus AI Details
10.17.2 Tempus AI Major Business
10.17.3 Tempus AI Tumor Biomarker Testing Product and Services
10.17.4 Tempus AI Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.17.5 Tempus AI Recent Developments/Updates
10.17.6 Tempus AI Competitive Strengths & Weaknesses
10.18 Natera
10.18.1 Natera Details
10.18.2 Natera Major Business
10.18.3 Natera Tumor Biomarker Testing Product and Services
10.18.4 Natera Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.18.5 Natera Recent Developments/Updates
10.18.6 Natera Competitive Strengths & Weaknesses
10.19 Personalis
10.19.1 Personalis Details
10.19.2 Personalis Major Business
10.19.3 Personalis Tumor Biomarker Testing Product and Services
10.19.4 Personalis Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.19.5 Personalis Recent Developments/Updates
10.19.6 Personalis Competitive Strengths & Weaknesses
10.20 Invivoscribe
10.20.1 Invivoscribe Details
10.20.2 Invivoscribe Major Business
10.20.3 Invivoscribe Tumor Biomarker Testing Product and Services
10.20.4 Invivoscribe Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.20.5 Invivoscribe Recent Developments/Updates
10.20.6 Invivoscribe Competitive Strengths & Weaknesses
10.21 Biocartis
10.21.1 Biocartis Details
10.21.2 Biocartis Major Business
10.21.3 Biocartis Tumor Biomarker Testing Product and Services
10.21.4 Biocartis Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.21.5 Biocartis Recent Developments/Updates
10.21.6 Biocartis Competitive Strengths & Weaknesses
10.22 Sysmex
10.22.1 Sysmex Details
10.22.2 Sysmex Major Business
10.22.3 Sysmex Tumor Biomarker Testing Product and Services
10.22.4 Sysmex Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.22.5 Sysmex Recent Developments/Updates
10.22.6 Sysmex Competitive Strengths & Weaknesses
10.23 Leica Biosystems
10.23.1 Leica Biosystems Details
10.23.2 Leica Biosystems Major Business
10.23.3 Leica Biosystems Tumor Biomarker Testing Product and Services
10.23.4 Leica Biosystems Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.23.5 Leica Biosystems Recent Developments/Updates
10.23.6 Leica Biosystems Competitive Strengths & Weaknesses
10.24 Cepheid
10.24.1 Cepheid Details
10.24.2 Cepheid Major Business
10.24.3 Cepheid Tumor Biomarker Testing Product and Services
10.24.4 Cepheid Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.24.5 Cepheid Recent Developments/Updates
10.24.6 Cepheid Competitive Strengths & Weaknesses
10.25 Menarini Silicon Biosystems
10.25.1 Menarini Silicon Biosystems Details
10.25.2 Menarini Silicon Biosystems Major Business
10.25.3 Menarini Silicon Biosystems Tumor Biomarker Testing Product and Services
10.25.4 Menarini Silicon Biosystems Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.25.5 Menarini Silicon Biosystems Recent Developments/Updates
10.25.6 Menarini Silicon Biosystems Competitive Strengths & Weaknesses
10.26 Veracyte
10.26.1 Veracyte Details
10.26.2 Veracyte Major Business
10.26.3 Veracyte Tumor Biomarker Testing Product and Services
10.26.4 Veracyte Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.26.5 Veracyte Recent Developments/Updates
10.26.6 Veracyte Competitive Strengths & Weaknesses
10.27 Castle Biosciences
10.27.1 Castle Biosciences Details
10.27.2 Castle Biosciences Major Business
10.27.3 Castle Biosciences Tumor Biomarker Testing Product and Services
10.27.4 Castle Biosciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.27.5 Castle Biosciences Recent Developments/Updates
10.27.6 Castle Biosciences Competitive Strengths & Weaknesses
10.28 OncoDNA
10.28.1 OncoDNA Details
10.28.2 OncoDNA Major Business
10.28.3 OncoDNA Tumor Biomarker Testing Product and Services
10.28.4 OncoDNA Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.28.5 OncoDNA Recent Developments/Updates
10.28.6 OncoDNA Competitive Strengths & Weaknesses
10.29 ACT Genomics
10.29.1 ACT Genomics Details
10.29.2 ACT Genomics Major Business
10.29.3 ACT Genomics Tumor Biomarker Testing Product and Services
10.29.4 ACT Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.29.5 ACT Genomics Recent Developments/Updates
10.29.6 ACT Genomics Competitive Strengths & Weaknesses
10.30 GC Genome
10.30.1 GC Genome Details
10.30.2 GC Genome Major Business
10.30.3 GC Genome Tumor Biomarker Testing Product and Services
10.30.4 GC Genome Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.30.5 GC Genome Recent Developments/Updates
10.30.6 GC Genome Competitive Strengths & Weaknesses
10.31 Burning Rock
10.31.1 Burning Rock Details
10.31.2 Burning Rock Major Business
10.31.3 Burning Rock Tumor Biomarker Testing Product and Services
10.31.4 Burning Rock Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.31.5 Burning Rock Recent Developments/Updates
10.31.6 Burning Rock Competitive Strengths & Weaknesses
10.32 Amoy Diagnostics
10.32.1 Amoy Diagnostics Details
10.32.2 Amoy Diagnostics Major Business
10.32.3 Amoy Diagnostics Tumor Biomarker Testing Product and Services
10.32.4 Amoy Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.32.5 Amoy Diagnostics Recent Developments/Updates
10.32.6 Amoy Diagnostics Competitive Strengths & Weaknesses
10.33 Genetron Health
10.33.1 Genetron Health Details
10.33.2 Genetron Health Major Business
10.33.3 Genetron Health Tumor Biomarker Testing Product and Services
10.33.4 Genetron Health Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.33.5 Genetron Health Recent Developments/Updates
10.33.6 Genetron Health Competitive Strengths & Weaknesses
10.34 3DMed Diagnostics
10.34.1 3DMed Diagnostics Details
10.34.2 3DMed Diagnostics Major Business
10.34.3 3DMed Diagnostics Tumor Biomarker Testing Product and Services
10.34.4 3DMed Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.34.5 3DMed Diagnostics Recent Developments/Updates
10.34.6 3DMed Diagnostics Competitive Strengths & Weaknesses
10.35 Singlera Genomics
10.35.1 Singlera Genomics Details
10.35.2 Singlera Genomics Major Business
10.35.3 Singlera Genomics Tumor Biomarker Testing Product and Services
10.35.4 Singlera Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.35.5 Singlera Genomics Recent Developments/Updates
10.35.6 Singlera Genomics Competitive Strengths & Weaknesses
10.36 BGI Genomics
10.36.1 BGI Genomics Details
10.36.2 BGI Genomics Major Business
10.36.3 BGI Genomics Tumor Biomarker Testing Product and Services
10.36.4 BGI Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.36.5 BGI Genomics Recent Developments/Updates
10.36.6 BGI Genomics Competitive Strengths & Weaknesses
10.37 Geneseeq
10.37.1 Geneseeq Details
10.37.2 Geneseeq Major Business
10.37.3 Geneseeq Tumor Biomarker Testing Product and Services
10.37.4 Geneseeq Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.37.5 Geneseeq Recent Developments/Updates
10.37.6 Geneseeq Competitive Strengths & Weaknesses
10.38 Genecast
10.38.1 Genecast Details
10.38.2 Genecast Major Business
10.38.3 Genecast Tumor Biomarker Testing Product and Services
10.38.4 Genecast Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026)
10.38.5 Genecast Recent Developments/Updates
10.38.6 Genecast Competitive Strengths & Weaknesses
11 INDUSTRY CHAIN ANALYSIS
11.1 Tumor Biomarker Testing Industry Chain
11.2 Tumor Biomarker Testing Upstream Analysis
11.3 Tumor Biomarker Testing Midstream Analysis
11.4 Tumor Biomarker Testing Downstream Analysis
12 RESEARCH FINDINGS AND CONCLUSION
13 APPENDIX
13.1 Methodology
13.2 Research Process and Data Source
13.3 Disclaimer
LIST OF TABLES
Table 1. World Tumor Biomarker Testing Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Tumor Biomarker Testing Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Tumor Biomarker Testing Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Tumor Biomarker Testing Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Tumor Biomarker Testing Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Tumor Biomarker Testing Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Tumor Biomarker Testing Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Tumor Biomarker Testing Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Tumor Biomarker Testing Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Tumor Biomarker Testing Players in 2025
Table 12. World Tumor Biomarker Testing Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Tumor Biomarker Testing Company Evaluation Quadrant
Table 14. Head Office of Key Tumor Biomarker Testing Players
Table 15. Tumor Biomarker Testing Market: Company Product Type Footprint
Table 16. Tumor Biomarker Testing Market: Company Product Application Footprint
Table 17. Tumor Biomarker Testing Mergers & Acquisitions Activity
Table 18. United States VS China Tumor Biomarker Testing Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Tumor Biomarker Testing Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Tumor Biomarker Testing Companies, Headquarters (States, Country)
Table 21. United States Based Companies Tumor Biomarker Testing Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Tumor Biomarker Testing Revenue Market Share (2021-2026)
Table 23. China Based Tumor Biomarker Testing Companies, Headquarters (Province, Country)
Table 24. China Based Companies Tumor Biomarker Testing Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Tumor Biomarker Testing Revenue Market Share (2021-2026)
Table 26. Rest of World Based Tumor Biomarker Testing Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Tumor Biomarker Testing Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Tumor Biomarker Testing Revenue Market Share (2021-2026)
Table 29. World Tumor Biomarker Testing Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Tumor Biomarker Testing Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Tumor Biomarker Testing Market Size by Type (2027-2032) & (USD Million)
Table 32. World Tumor Biomarker Testing Market Size by Sample Source, (USD Million), 2021 & 2025 & 2032
Table 33. World Tumor Biomarker Testing Market Size Value by Sample Source (2021-2026) & (USD Million)
Table 34. World Tumor Biomarker Testing Market Size by Sample Source (2027-2032) & (USD Million)
Table 35. World Tumor Biomarker Testing Market Size by Delivery Model, (USD Million), 2021 & 2025 & 2032
Table 36. World Tumor Biomarker Testing Market Size Value by Delivery Model (2021-2026) & (USD Million)
Table 37. World Tumor Biomarker Testing Market Size by Delivery Model (2027-2032) & (USD Million)
Table 38. World Tumor Biomarker Testing Market Size by Detection Technology, (USD Million), 2021 & 2025 & 2032
Table 39. World Tumor Biomarker Testing Market Size Value by Detection Technology (2021-2026) & (USD Million)
Table 40. World Tumor Biomarker Testing Market Size by Detection Technology (2027-2032) & (USD Million)
Table 41. World Tumor Biomarker Testing Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 42. World Tumor Biomarker Testing Market Size by Application (2021-2026) & (USD Million)
Table 43. World Tumor Biomarker Testing Market Size by Application (2027-2032) & (USD Million)
Table 44. Abbott Laboratories Basic Information, Manufacturing Base and Competitors
Table 45. Abbott Laboratories Major Business
Table 46. Abbott Laboratories Tumor Biomarker Testing Product and Services
Table 47. Abbott Laboratories Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 48. Abbott Laboratories Recent Developments/Updates
Table 49. Abbott Laboratories Competitive Strengths & Weaknesses
Table 50. Agilent Technologies Basic Information, Manufacturing Base and Competitors
Table 51. Agilent Technologies Major Business
Table 52. Agilent Technologies Tumor Biomarker Testing Product and Services
Table 53. Agilent Technologies Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 54. Agilent Technologies Recent Developments/Updates
Table 55. Agilent Technologies Competitive Strengths & Weaknesses
Table 56. Roche Basic Information, Manufacturing Base and Competitors
Table 57. Roche Major Business
Table 58. Roche Tumor Biomarker Testing Product and Services
Table 59. Roche Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 60. Roche Recent Developments/Updates
Table 61. Roche Competitive Strengths & Weaknesses
Table 62. Thermo Fisher Scientific Basic Information, Manufacturing Base and Competitors
Table 63. Thermo Fisher Scientific Major Business
Table 64. Thermo Fisher Scientific Tumor Biomarker Testing Product and Services
Table 65. Thermo Fisher Scientific Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 66. Thermo Fisher Scientific Recent Developments/Updates
Table 67. Thermo Fisher Scientific Competitive Strengths & Weaknesses
Table 68. QIAGEN Basic Information, Manufacturing Base and Competitors
Table 69. QIAGEN Major Business
Table 70. QIAGEN Tumor Biomarker Testing Product and Services
Table 71. QIAGEN Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 72. QIAGEN Recent Developments/Updates
Table 73. QIAGEN Competitive Strengths & Weaknesses
Table 74. Illumina Basic Information, Manufacturing Base and Competitors
Table 75. Illumina Major Business
Table 76. Illumina Tumor Biomarker Testing Product and Services
Table 77. Illumina Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 78. Illumina Recent Developments/Updates
Table 79. Illumina Competitive Strengths & Weaknesses
Table 80. DiaSorin Basic Information, Manufacturing Base and Competitors
Table 81. DiaSorin Major Business
Table 82. DiaSorin Tumor Biomarker Testing Product and Services
Table 83. DiaSorin Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 84. DiaSorin Recent Developments/Updates
Table 85. DiaSorin Competitive Strengths & Weaknesses
Table 86. Fujirebio Basic Information, Manufacturing Base and Competitors
Table 87. Fujirebio Major Business
Table 88. Fujirebio Tumor Biomarker Testing Product and Services
Table 89. Fujirebio Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 90. Fujirebio Recent Developments/Updates
Table 91. Fujirebio Competitive Strengths & Weaknesses
Table 92. Siemens Healthineers Basic Information, Manufacturing Base and Competitors
Table 93. Siemens Healthineers Major Business
Table 94. Siemens Healthineers Tumor Biomarker Testing Product and Services
Table 95. Siemens Healthineers Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 96. Siemens Healthineers Recent Developments/Updates
Table 97. Siemens Healthineers Competitive Strengths & Weaknesses
Table 98. Quest Diagnostics Basic Information, Manufacturing Base and Competitors
Table 99. Quest Diagnostics Major Business
Table 100. Quest Diagnostics Tumor Biomarker Testing Product and Services
Table 101. Quest Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 102. Quest Diagnostics Recent Developments/Updates
Table 103. Quest Diagnostics Competitive Strengths & Weaknesses
Table 104. Labcorp Basic Information, Manufacturing Base and Competitors
Table 105. Labcorp Major Business
Table 106. Labcorp Tumor Biomarker Testing Product and Services
Table 107. Labcorp Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 108. Labcorp Recent Developments/Updates
Table 109. Labcorp Competitive Strengths & Weaknesses
Table 110. NeoGenomics Basic Information, Manufacturing Base and Competitors
Table 111. NeoGenomics Major Business
Table 112. NeoGenomics Tumor Biomarker Testing Product and Services
Table 113. NeoGenomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 114. NeoGenomics Recent Developments/Updates
Table 115. NeoGenomics Competitive Strengths & Weaknesses
Table 116. Exact Sciences Basic Information, Manufacturing Base and Competitors
Table 117. Exact Sciences Major Business
Table 118. Exact Sciences Tumor Biomarker Testing Product and Services
Table 119. Exact Sciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 120. Exact Sciences Recent Developments/Updates
Table 121. Exact Sciences Competitive Strengths & Weaknesses
Table 122. Myriad Genetics Basic Information, Manufacturing Base and Competitors
Table 123. Myriad Genetics Major Business
Table 124. Myriad Genetics Tumor Biomarker Testing Product and Services
Table 125. Myriad Genetics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 126. Myriad Genetics Recent Developments/Updates
Table 127. Myriad Genetics Competitive Strengths & Weaknesses
Table 128. Guardant Health Basic Information, Manufacturing Base and Competitors
Table 129. Guardant Health Major Business
Table 130. Guardant Health Tumor Biomarker Testing Product and Services
Table 131. Guardant Health Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 132. Guardant Health Recent Developments/Updates
Table 133. Guardant Health Competitive Strengths & Weaknesses
Table 134. Caris Life Sciences Basic Information, Manufacturing Base and Competitors
Table 135. Caris Life Sciences Major Business
Table 136. Caris Life Sciences Tumor Biomarker Testing Product and Services
Table 137. Caris Life Sciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 138. Caris Life Sciences Recent Developments/Updates
Table 139. Caris Life Sciences Competitive Strengths & Weaknesses
Table 140. Tempus AI Basic Information, Manufacturing Base and Competitors
Table 141. Tempus AI Major Business
Table 142. Tempus AI Tumor Biomarker Testing Product and Services
Table 143. Tempus AI Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 144. Tempus AI Recent Developments/Updates
Table 145. Tempus AI Competitive Strengths & Weaknesses
Table 146. Natera Basic Information, Manufacturing Base and Competitors
Table 147. Natera Major Business
Table 148. Natera Tumor Biomarker Testing Product and Services
Table 149. Natera Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 150. Natera Recent Developments/Updates
Table 151. Natera Competitive Strengths & Weaknesses
Table 152. Personalis Basic Information, Manufacturing Base and Competitors
Table 153. Personalis Major Business
Table 154. Personalis Tumor Biomarker Testing Product and Services
Table 155. Personalis Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 156. Personalis Recent Developments/Updates
Table 157. Personalis Competitive Strengths & Weaknesses
Table 158. Invivoscribe Basic Information, Manufacturing Base and Competitors
Table 159. Invivoscribe Major Business
Table 160. Invivoscribe Tumor Biomarker Testing Product and Services
Table 161. Invivoscribe Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 162. Invivoscribe Recent Developments/Updates
Table 163. Invivoscribe Competitive Strengths & Weaknesses
Table 164. Biocartis Basic Information, Manufacturing Base and Competitors
Table 165. Biocartis Major Business
Table 166. Biocartis Tumor Biomarker Testing Product and Services
Table 167. Biocartis Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 168. Biocartis Recent Developments/Updates
Table 169. Biocartis Competitive Strengths & Weaknesses
Table 170. Sysmex Basic Information, Manufacturing Base and Competitors
Table 171. Sysmex Major Business
Table 172. Sysmex Tumor Biomarker Testing Product and Services
Table 173. Sysmex Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 174. Sysmex Recent Developments/Updates
Table 175. Sysmex Competitive Strengths & Weaknesses
Table 176. Leica Biosystems Basic Information, Manufacturing Base and Competitors
Table 177. Leica Biosystems Major Business
Table 178. Leica Biosystems Tumor Biomarker Testing Product and Services
Table 179. Leica Biosystems Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 180. Leica Biosystems Recent Developments/Updates
Table 181. Leica Biosystems Competitive Strengths & Weaknesses
Table 182. Cepheid Basic Information, Manufacturing Base and Competitors
Table 183. Cepheid Major Business
Table 184. Cepheid Tumor Biomarker Testing Product and Services
Table 185. Cepheid Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 186. Cepheid Recent Developments/Updates
Table 187. Cepheid Competitive Strengths & Weaknesses
Table 188. Menarini Silicon Biosystems Basic Information, Manufacturing Base and Competitors
Table 189. Menarini Silicon Biosystems Major Business
Table 190. Menarini Silicon Biosystems Tumor Biomarker Testing Product and Services
Table 191. Menarini Silicon Biosystems Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 192. Menarini Silicon Biosystems Recent Developments/Updates
Table 193. Menarini Silicon Biosystems Competitive Strengths & Weaknesses
Table 194. Veracyte Basic Information, Manufacturing Base and Competitors
Table 195. Veracyte Major Business
Table 196. Veracyte Tumor Biomarker Testing Product and Services
Table 197. Veracyte Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 198. Veracyte Recent Developments/Updates
Table 199. Veracyte Competitive Strengths & Weaknesses
Table 200. Castle Biosciences Basic Information, Manufacturing Base and Competitors
Table 201. Castle Biosciences Major Business
Table 202. Castle Biosciences Tumor Biomarker Testing Product and Services
Table 203. Castle Biosciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 204. Castle Biosciences Recent Developments/Updates
Table 205. Castle Biosciences Competitive Strengths & Weaknesses
Table 206. OncoDNA Basic Information, Manufacturing Base and Competitors
Table 207. OncoDNA Major Business
Table 208. OncoDNA Tumor Biomarker Testing Product and Services
Table 209. OncoDNA Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 210. OncoDNA Recent Developments/Updates
Table 211. OncoDNA Competitive Strengths & Weaknesses
Table 212. ACT Genomics Basic Information, Manufacturing Base and Competitors
Table 213. ACT Genomics Major Business
Table 214. ACT Genomics Tumor Biomarker Testing Product and Services
Table 215. ACT Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 216. ACT Genomics Recent Developments/Updates
Table 217. ACT Genomics Competitive Strengths & Weaknesses
Table 218. GC Genome Basic Information, Manufacturing Base and Competitors
Table 219. GC Genome Major Business
Table 220. GC Genome Tumor Biomarker Testing Product and Services
Table 221. GC Genome Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 222. GC Genome Recent Developments/Updates
Table 223. GC Genome Competitive Strengths & Weaknesses
Table 224. Burning Rock Basic Information, Manufacturing Base and Competitors
Table 225. Burning Rock Major Business
Table 226. Burning Rock Tumor Biomarker Testing Product and Services
Table 227. Burning Rock Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 228. Burning Rock Recent Developments/Updates
Table 229. Burning Rock Competitive Strengths & Weaknesses
Table 230. Amoy Diagnostics Basic Information, Manufacturing Base and Competitors
Table 231. Amoy Diagnostics Major Business
Table 232. Amoy Diagnostics Tumor Biomarker Testing Product and Services
Table 233. Amoy Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 234. Amoy Diagnostics Recent Developments/Updates
Table 235. Amoy Diagnostics Competitive Strengths & Weaknesses
Table 236. Genetron Health Basic Information, Manufacturing Base and Competitors
Table 237. Genetron Health Major Business
Table 238. Genetron Health Tumor Biomarker Testing Product and Services
Table 239. Genetron Health Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 240. Genetron Health Recent Developments/Updates
Table 241. Genetron Health Competitive Strengths & Weaknesses
Table 242. 3DMed Diagnostics Basic Information, Manufacturing Base and Competitors
Table 243. 3DMed Diagnostics Major Business
Table 244. 3DMed Diagnostics Tumor Biomarker Testing Product and Services
Table 245. 3DMed Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 246. 3DMed Diagnostics Recent Developments/Updates
Table 247. 3DMed Diagnostics Competitive Strengths & Weaknesses
Table 248. Singlera Genomics Basic Information, Manufacturing Base and Competitors
Table 249. Singlera Genomics Major Business
Table 250. Singlera Genomics Tumor Biomarker Testing Product and Services
Table 251. Singlera Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 252. Singlera Genomics Recent Developments/Updates
Table 253. Singlera Genomics Competitive Strengths & Weaknesses
Table 254. BGI Genomics Basic Information, Manufacturing Base and Competitors
Table 255. BGI Genomics Major Business
Table 256. BGI Genomics Tumor Biomarker Testing Product and Services
Table 257. BGI Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 258. BGI Genomics Recent Developments/Updates
Table 259. BGI Genomics Competitive Strengths & Weaknesses
Table 260. Geneseeq Basic Information, Manufacturing Base and Competitors
Table 261. Geneseeq Major Business
Table 262. Geneseeq Tumor Biomarker Testing Product and Services
Table 263. Geneseeq Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 264. Geneseeq Recent Developments/Updates
Table 265. Geneseeq Competitive Strengths & Weaknesses
Table 266. Genecast Basic Information, Manufacturing Base and Competitors
Table 267. Genecast Major Business
Table 268. Genecast Tumor Biomarker Testing Product and Services
Table 269. Genecast Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 270. Genecast Recent Developments/Updates
Table 271. Genecast Competitive Strengths & Weaknesses
Table 272. Global Key Players of Tumor Biomarker Testing Upstream (Raw Materials)
Table 273. Global Tumor Biomarker Testing Typical Customers
Table 1. World Tumor Biomarker Testing Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Tumor Biomarker Testing Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Tumor Biomarker Testing Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Tumor Biomarker Testing Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Tumor Biomarker Testing Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Tumor Biomarker Testing Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Tumor Biomarker Testing Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Tumor Biomarker Testing Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Tumor Biomarker Testing Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Tumor Biomarker Testing Players in 2025
Table 12. World Tumor Biomarker Testing Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Tumor Biomarker Testing Company Evaluation Quadrant
Table 14. Head Office of Key Tumor Biomarker Testing Players
Table 15. Tumor Biomarker Testing Market: Company Product Type Footprint
Table 16. Tumor Biomarker Testing Market: Company Product Application Footprint
Table 17. Tumor Biomarker Testing Mergers & Acquisitions Activity
Table 18. United States VS China Tumor Biomarker Testing Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Tumor Biomarker Testing Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Tumor Biomarker Testing Companies, Headquarters (States, Country)
Table 21. United States Based Companies Tumor Biomarker Testing Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Tumor Biomarker Testing Revenue Market Share (2021-2026)
Table 23. China Based Tumor Biomarker Testing Companies, Headquarters (Province, Country)
Table 24. China Based Companies Tumor Biomarker Testing Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Tumor Biomarker Testing Revenue Market Share (2021-2026)
Table 26. Rest of World Based Tumor Biomarker Testing Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Tumor Biomarker Testing Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Tumor Biomarker Testing Revenue Market Share (2021-2026)
Table 29. World Tumor Biomarker Testing Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Tumor Biomarker Testing Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Tumor Biomarker Testing Market Size by Type (2027-2032) & (USD Million)
Table 32. World Tumor Biomarker Testing Market Size by Sample Source, (USD Million), 2021 & 2025 & 2032
Table 33. World Tumor Biomarker Testing Market Size Value by Sample Source (2021-2026) & (USD Million)
Table 34. World Tumor Biomarker Testing Market Size by Sample Source (2027-2032) & (USD Million)
Table 35. World Tumor Biomarker Testing Market Size by Delivery Model, (USD Million), 2021 & 2025 & 2032
Table 36. World Tumor Biomarker Testing Market Size Value by Delivery Model (2021-2026) & (USD Million)
Table 37. World Tumor Biomarker Testing Market Size by Delivery Model (2027-2032) & (USD Million)
Table 38. World Tumor Biomarker Testing Market Size by Detection Technology, (USD Million), 2021 & 2025 & 2032
Table 39. World Tumor Biomarker Testing Market Size Value by Detection Technology (2021-2026) & (USD Million)
Table 40. World Tumor Biomarker Testing Market Size by Detection Technology (2027-2032) & (USD Million)
Table 41. World Tumor Biomarker Testing Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 42. World Tumor Biomarker Testing Market Size by Application (2021-2026) & (USD Million)
Table 43. World Tumor Biomarker Testing Market Size by Application (2027-2032) & (USD Million)
Table 44. Abbott Laboratories Basic Information, Manufacturing Base and Competitors
Table 45. Abbott Laboratories Major Business
Table 46. Abbott Laboratories Tumor Biomarker Testing Product and Services
Table 47. Abbott Laboratories Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 48. Abbott Laboratories Recent Developments/Updates
Table 49. Abbott Laboratories Competitive Strengths & Weaknesses
Table 50. Agilent Technologies Basic Information, Manufacturing Base and Competitors
Table 51. Agilent Technologies Major Business
Table 52. Agilent Technologies Tumor Biomarker Testing Product and Services
Table 53. Agilent Technologies Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 54. Agilent Technologies Recent Developments/Updates
Table 55. Agilent Technologies Competitive Strengths & Weaknesses
Table 56. Roche Basic Information, Manufacturing Base and Competitors
Table 57. Roche Major Business
Table 58. Roche Tumor Biomarker Testing Product and Services
Table 59. Roche Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 60. Roche Recent Developments/Updates
Table 61. Roche Competitive Strengths & Weaknesses
Table 62. Thermo Fisher Scientific Basic Information, Manufacturing Base and Competitors
Table 63. Thermo Fisher Scientific Major Business
Table 64. Thermo Fisher Scientific Tumor Biomarker Testing Product and Services
Table 65. Thermo Fisher Scientific Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 66. Thermo Fisher Scientific Recent Developments/Updates
Table 67. Thermo Fisher Scientific Competitive Strengths & Weaknesses
Table 68. QIAGEN Basic Information, Manufacturing Base and Competitors
Table 69. QIAGEN Major Business
Table 70. QIAGEN Tumor Biomarker Testing Product and Services
Table 71. QIAGEN Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 72. QIAGEN Recent Developments/Updates
Table 73. QIAGEN Competitive Strengths & Weaknesses
Table 74. Illumina Basic Information, Manufacturing Base and Competitors
Table 75. Illumina Major Business
Table 76. Illumina Tumor Biomarker Testing Product and Services
Table 77. Illumina Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 78. Illumina Recent Developments/Updates
Table 79. Illumina Competitive Strengths & Weaknesses
Table 80. DiaSorin Basic Information, Manufacturing Base and Competitors
Table 81. DiaSorin Major Business
Table 82. DiaSorin Tumor Biomarker Testing Product and Services
Table 83. DiaSorin Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 84. DiaSorin Recent Developments/Updates
Table 85. DiaSorin Competitive Strengths & Weaknesses
Table 86. Fujirebio Basic Information, Manufacturing Base and Competitors
Table 87. Fujirebio Major Business
Table 88. Fujirebio Tumor Biomarker Testing Product and Services
Table 89. Fujirebio Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 90. Fujirebio Recent Developments/Updates
Table 91. Fujirebio Competitive Strengths & Weaknesses
Table 92. Siemens Healthineers Basic Information, Manufacturing Base and Competitors
Table 93. Siemens Healthineers Major Business
Table 94. Siemens Healthineers Tumor Biomarker Testing Product and Services
Table 95. Siemens Healthineers Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 96. Siemens Healthineers Recent Developments/Updates
Table 97. Siemens Healthineers Competitive Strengths & Weaknesses
Table 98. Quest Diagnostics Basic Information, Manufacturing Base and Competitors
Table 99. Quest Diagnostics Major Business
Table 100. Quest Diagnostics Tumor Biomarker Testing Product and Services
Table 101. Quest Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 102. Quest Diagnostics Recent Developments/Updates
Table 103. Quest Diagnostics Competitive Strengths & Weaknesses
Table 104. Labcorp Basic Information, Manufacturing Base and Competitors
Table 105. Labcorp Major Business
Table 106. Labcorp Tumor Biomarker Testing Product and Services
Table 107. Labcorp Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 108. Labcorp Recent Developments/Updates
Table 109. Labcorp Competitive Strengths & Weaknesses
Table 110. NeoGenomics Basic Information, Manufacturing Base and Competitors
Table 111. NeoGenomics Major Business
Table 112. NeoGenomics Tumor Biomarker Testing Product and Services
Table 113. NeoGenomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 114. NeoGenomics Recent Developments/Updates
Table 115. NeoGenomics Competitive Strengths & Weaknesses
Table 116. Exact Sciences Basic Information, Manufacturing Base and Competitors
Table 117. Exact Sciences Major Business
Table 118. Exact Sciences Tumor Biomarker Testing Product and Services
Table 119. Exact Sciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 120. Exact Sciences Recent Developments/Updates
Table 121. Exact Sciences Competitive Strengths & Weaknesses
Table 122. Myriad Genetics Basic Information, Manufacturing Base and Competitors
Table 123. Myriad Genetics Major Business
Table 124. Myriad Genetics Tumor Biomarker Testing Product and Services
Table 125. Myriad Genetics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 126. Myriad Genetics Recent Developments/Updates
Table 127. Myriad Genetics Competitive Strengths & Weaknesses
Table 128. Guardant Health Basic Information, Manufacturing Base and Competitors
Table 129. Guardant Health Major Business
Table 130. Guardant Health Tumor Biomarker Testing Product and Services
Table 131. Guardant Health Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 132. Guardant Health Recent Developments/Updates
Table 133. Guardant Health Competitive Strengths & Weaknesses
Table 134. Caris Life Sciences Basic Information, Manufacturing Base and Competitors
Table 135. Caris Life Sciences Major Business
Table 136. Caris Life Sciences Tumor Biomarker Testing Product and Services
Table 137. Caris Life Sciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 138. Caris Life Sciences Recent Developments/Updates
Table 139. Caris Life Sciences Competitive Strengths & Weaknesses
Table 140. Tempus AI Basic Information, Manufacturing Base and Competitors
Table 141. Tempus AI Major Business
Table 142. Tempus AI Tumor Biomarker Testing Product and Services
Table 143. Tempus AI Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 144. Tempus AI Recent Developments/Updates
Table 145. Tempus AI Competitive Strengths & Weaknesses
Table 146. Natera Basic Information, Manufacturing Base and Competitors
Table 147. Natera Major Business
Table 148. Natera Tumor Biomarker Testing Product and Services
Table 149. Natera Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 150. Natera Recent Developments/Updates
Table 151. Natera Competitive Strengths & Weaknesses
Table 152. Personalis Basic Information, Manufacturing Base and Competitors
Table 153. Personalis Major Business
Table 154. Personalis Tumor Biomarker Testing Product and Services
Table 155. Personalis Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 156. Personalis Recent Developments/Updates
Table 157. Personalis Competitive Strengths & Weaknesses
Table 158. Invivoscribe Basic Information, Manufacturing Base and Competitors
Table 159. Invivoscribe Major Business
Table 160. Invivoscribe Tumor Biomarker Testing Product and Services
Table 161. Invivoscribe Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 162. Invivoscribe Recent Developments/Updates
Table 163. Invivoscribe Competitive Strengths & Weaknesses
Table 164. Biocartis Basic Information, Manufacturing Base and Competitors
Table 165. Biocartis Major Business
Table 166. Biocartis Tumor Biomarker Testing Product and Services
Table 167. Biocartis Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 168. Biocartis Recent Developments/Updates
Table 169. Biocartis Competitive Strengths & Weaknesses
Table 170. Sysmex Basic Information, Manufacturing Base and Competitors
Table 171. Sysmex Major Business
Table 172. Sysmex Tumor Biomarker Testing Product and Services
Table 173. Sysmex Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 174. Sysmex Recent Developments/Updates
Table 175. Sysmex Competitive Strengths & Weaknesses
Table 176. Leica Biosystems Basic Information, Manufacturing Base and Competitors
Table 177. Leica Biosystems Major Business
Table 178. Leica Biosystems Tumor Biomarker Testing Product and Services
Table 179. Leica Biosystems Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 180. Leica Biosystems Recent Developments/Updates
Table 181. Leica Biosystems Competitive Strengths & Weaknesses
Table 182. Cepheid Basic Information, Manufacturing Base and Competitors
Table 183. Cepheid Major Business
Table 184. Cepheid Tumor Biomarker Testing Product and Services
Table 185. Cepheid Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 186. Cepheid Recent Developments/Updates
Table 187. Cepheid Competitive Strengths & Weaknesses
Table 188. Menarini Silicon Biosystems Basic Information, Manufacturing Base and Competitors
Table 189. Menarini Silicon Biosystems Major Business
Table 190. Menarini Silicon Biosystems Tumor Biomarker Testing Product and Services
Table 191. Menarini Silicon Biosystems Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 192. Menarini Silicon Biosystems Recent Developments/Updates
Table 193. Menarini Silicon Biosystems Competitive Strengths & Weaknesses
Table 194. Veracyte Basic Information, Manufacturing Base and Competitors
Table 195. Veracyte Major Business
Table 196. Veracyte Tumor Biomarker Testing Product and Services
Table 197. Veracyte Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 198. Veracyte Recent Developments/Updates
Table 199. Veracyte Competitive Strengths & Weaknesses
Table 200. Castle Biosciences Basic Information, Manufacturing Base and Competitors
Table 201. Castle Biosciences Major Business
Table 202. Castle Biosciences Tumor Biomarker Testing Product and Services
Table 203. Castle Biosciences Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 204. Castle Biosciences Recent Developments/Updates
Table 205. Castle Biosciences Competitive Strengths & Weaknesses
Table 206. OncoDNA Basic Information, Manufacturing Base and Competitors
Table 207. OncoDNA Major Business
Table 208. OncoDNA Tumor Biomarker Testing Product and Services
Table 209. OncoDNA Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 210. OncoDNA Recent Developments/Updates
Table 211. OncoDNA Competitive Strengths & Weaknesses
Table 212. ACT Genomics Basic Information, Manufacturing Base and Competitors
Table 213. ACT Genomics Major Business
Table 214. ACT Genomics Tumor Biomarker Testing Product and Services
Table 215. ACT Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 216. ACT Genomics Recent Developments/Updates
Table 217. ACT Genomics Competitive Strengths & Weaknesses
Table 218. GC Genome Basic Information, Manufacturing Base and Competitors
Table 219. GC Genome Major Business
Table 220. GC Genome Tumor Biomarker Testing Product and Services
Table 221. GC Genome Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 222. GC Genome Recent Developments/Updates
Table 223. GC Genome Competitive Strengths & Weaknesses
Table 224. Burning Rock Basic Information, Manufacturing Base and Competitors
Table 225. Burning Rock Major Business
Table 226. Burning Rock Tumor Biomarker Testing Product and Services
Table 227. Burning Rock Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 228. Burning Rock Recent Developments/Updates
Table 229. Burning Rock Competitive Strengths & Weaknesses
Table 230. Amoy Diagnostics Basic Information, Manufacturing Base and Competitors
Table 231. Amoy Diagnostics Major Business
Table 232. Amoy Diagnostics Tumor Biomarker Testing Product and Services
Table 233. Amoy Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 234. Amoy Diagnostics Recent Developments/Updates
Table 235. Amoy Diagnostics Competitive Strengths & Weaknesses
Table 236. Genetron Health Basic Information, Manufacturing Base and Competitors
Table 237. Genetron Health Major Business
Table 238. Genetron Health Tumor Biomarker Testing Product and Services
Table 239. Genetron Health Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 240. Genetron Health Recent Developments/Updates
Table 241. Genetron Health Competitive Strengths & Weaknesses
Table 242. 3DMed Diagnostics Basic Information, Manufacturing Base and Competitors
Table 243. 3DMed Diagnostics Major Business
Table 244. 3DMed Diagnostics Tumor Biomarker Testing Product and Services
Table 245. 3DMed Diagnostics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 246. 3DMed Diagnostics Recent Developments/Updates
Table 247. 3DMed Diagnostics Competitive Strengths & Weaknesses
Table 248. Singlera Genomics Basic Information, Manufacturing Base and Competitors
Table 249. Singlera Genomics Major Business
Table 250. Singlera Genomics Tumor Biomarker Testing Product and Services
Table 251. Singlera Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 252. Singlera Genomics Recent Developments/Updates
Table 253. Singlera Genomics Competitive Strengths & Weaknesses
Table 254. BGI Genomics Basic Information, Manufacturing Base and Competitors
Table 255. BGI Genomics Major Business
Table 256. BGI Genomics Tumor Biomarker Testing Product and Services
Table 257. BGI Genomics Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 258. BGI Genomics Recent Developments/Updates
Table 259. BGI Genomics Competitive Strengths & Weaknesses
Table 260. Geneseeq Basic Information, Manufacturing Base and Competitors
Table 261. Geneseeq Major Business
Table 262. Geneseeq Tumor Biomarker Testing Product and Services
Table 263. Geneseeq Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 264. Geneseeq Recent Developments/Updates
Table 265. Geneseeq Competitive Strengths & Weaknesses
Table 266. Genecast Basic Information, Manufacturing Base and Competitors
Table 267. Genecast Major Business
Table 268. Genecast Tumor Biomarker Testing Product and Services
Table 269. Genecast Tumor Biomarker Testing Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 270. Genecast Recent Developments/Updates
Table 271. Genecast Competitive Strengths & Weaknesses
Table 272. Global Key Players of Tumor Biomarker Testing Upstream (Raw Materials)
Table 273. Global Tumor Biomarker Testing Typical Customers
LIST OF FIGURES
Figure 1. Tumor Biomarker Testing Picture
Figure 2. World Tumor Biomarker Testing Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Tumor Biomarker Testing Total Revenue (2021-2032) & (USD Million)
Figure 4. World Tumor Biomarker Testing Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Tumor Biomarker Testing Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Tumor Biomarker Testing Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Tumor Biomarker Testing Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Tumor Biomarker Testing Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Tumor Biomarker Testing Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Tumor Biomarker Testing Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Tumor Biomarker Testing Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Tumor Biomarker Testing Revenue (2021-2032) & (USD Million)
Figure 13. Tumor Biomarker Testing Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)
Figure 16. World Tumor Biomarker Testing Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)
Figure 18. China Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)
Figure 23. India Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Tumor Biomarker Testing by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Tumor Biomarker Testing Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Tumor Biomarker Testing Markets in 2025
Figure 27. United States VS China: Tumor Biomarker Testing Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Tumor Biomarker Testing Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Tumor Biomarker Testing Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Tumor Biomarker Testing Market Size Market Share by Type in 2025
Figure 31. DNA Biomarker Testing
Figure 32. RNA Biomarker Testing
Figure 33. Protein Biomarker Testing
Figure 34. Cell-based Biomarker Testing
Figure 35. Multi-analyte Biomarker Testing
Figure 36. World Tumor Biomarker Testing Market Size Market Share by Type (2021-2032)
Figure 37. World Tumor Biomarker Testing Market Size by Sample Source, (USD Million), 2021 & 2025 & 2032
Figure 38. World Tumor Biomarker Testing Market Size Market Share by Sample Source in 2025
Figure 39. Tissue-based Testing
Figure 40. Blood-based Testing
Figure 41. Bone Marrow-based Testing
Figure 42. Other Body Fluid-based Testing
Figure 43. World Tumor Biomarker Testing Market Size Market Share by Sample Source (2021-2032)
Figure 44. World Tumor Biomarker Testing Market Size by Delivery Model, (USD Million), 2021 & 2025 & 2032
Figure 45. World Tumor Biomarker Testing Market Size Market Share by Delivery Model in 2025
Figure 46. Central Laboratory Testing
Figure 47. Hospital In-house Testing
Figure 48. World Tumor Biomarker Testing Market Size Market Share by Delivery Model (2021-2032)
Figure 49. World Tumor Biomarker Testing Market Size by Detection Technology, (USD Million), 2021 & 2025 & 2032
Figure 50. World Tumor Biomarker Testing Market Size Market Share by Detection Technology in 2025
Figure 51. Sequencing-based Testing
Figure 52. PCR-based Testing
Figure 53. Immunoassay-based Testing
Figure 54. Hybridization-based Testing
Figure 55. Cell Analysis-based Testing
Figure 56. World Tumor Biomarker Testing Market Size Market Share by Detection Technology (2021-2032)
Figure 57. World Tumor Biomarker Testing Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 58. World Tumor Biomarker Testing Market Size Market Share by Application in 2025
Figure 59. Lung Cancer
Figure 60. Breast Cancer
Figure 61. Colorectal
Figure 62. Prostate Cancer
Figure 63. Blood Cancer
Figure 64. World Tumor Biomarker Testing Market Size Market Share by Application (2021-2032)
Figure 65. Tumor Biomarker Testing Industrial Chain
Figure 66. Methodology
Figure 67. Research Process and Data Source
Figure 1. Tumor Biomarker Testing Picture
Figure 2. World Tumor Biomarker Testing Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Tumor Biomarker Testing Total Revenue (2021-2032) & (USD Million)
Figure 4. World Tumor Biomarker Testing Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Tumor Biomarker Testing Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Tumor Biomarker Testing Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Tumor Biomarker Testing Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Tumor Biomarker Testing Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Tumor Biomarker Testing Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Tumor Biomarker Testing Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Tumor Biomarker Testing Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Tumor Biomarker Testing Revenue (2021-2032) & (USD Million)
Figure 13. Tumor Biomarker Testing Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)
Figure 16. World Tumor Biomarker Testing Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)
Figure 18. China Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)
Figure 23. India Tumor Biomarker Testing Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Tumor Biomarker Testing by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Tumor Biomarker Testing Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Tumor Biomarker Testing Markets in 2025
Figure 27. United States VS China: Tumor Biomarker Testing Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Tumor Biomarker Testing Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Tumor Biomarker Testing Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Tumor Biomarker Testing Market Size Market Share by Type in 2025
Figure 31. DNA Biomarker Testing
Figure 32. RNA Biomarker Testing
Figure 33. Protein Biomarker Testing
Figure 34. Cell-based Biomarker Testing
Figure 35. Multi-analyte Biomarker Testing
Figure 36. World Tumor Biomarker Testing Market Size Market Share by Type (2021-2032)
Figure 37. World Tumor Biomarker Testing Market Size by Sample Source, (USD Million), 2021 & 2025 & 2032
Figure 38. World Tumor Biomarker Testing Market Size Market Share by Sample Source in 2025
Figure 39. Tissue-based Testing
Figure 40. Blood-based Testing
Figure 41. Bone Marrow-based Testing
Figure 42. Other Body Fluid-based Testing
Figure 43. World Tumor Biomarker Testing Market Size Market Share by Sample Source (2021-2032)
Figure 44. World Tumor Biomarker Testing Market Size by Delivery Model, (USD Million), 2021 & 2025 & 2032
Figure 45. World Tumor Biomarker Testing Market Size Market Share by Delivery Model in 2025
Figure 46. Central Laboratory Testing
Figure 47. Hospital In-house Testing
Figure 48. World Tumor Biomarker Testing Market Size Market Share by Delivery Model (2021-2032)
Figure 49. World Tumor Biomarker Testing Market Size by Detection Technology, (USD Million), 2021 & 2025 & 2032
Figure 50. World Tumor Biomarker Testing Market Size Market Share by Detection Technology in 2025
Figure 51. Sequencing-based Testing
Figure 52. PCR-based Testing
Figure 53. Immunoassay-based Testing
Figure 54. Hybridization-based Testing
Figure 55. Cell Analysis-based Testing
Figure 56. World Tumor Biomarker Testing Market Size Market Share by Detection Technology (2021-2032)
Figure 57. World Tumor Biomarker Testing Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 58. World Tumor Biomarker Testing Market Size Market Share by Application in 2025
Figure 59. Lung Cancer
Figure 60. Breast Cancer
Figure 61. Colorectal
Figure 62. Prostate Cancer
Figure 63. Blood Cancer
Figure 64. World Tumor Biomarker Testing Market Size Market Share by Application (2021-2032)
Figure 65. Tumor Biomarker Testing Industrial Chain
Figure 66. Methodology
Figure 67. Research Process and Data Source
